Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Colorectal Dis ; 19(1): 67-75, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27610599

RESUMEN

AIM: The management of large non-pedunculated colorectal polyps (LNPCPs) is complex, with widespread variation in management and outcome, even amongst experienced clinicians. Variations in the assessment and decision-making processes are likely to be a major factor in this variability. The creation of a standardized minimum dataset to aid decision-making may therefore result in improved clinical management. METHOD: An official working group of 13 multidisciplinary specialists was appointed by the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG) to develop a minimum dataset on LNPCPs. The literature review used to structure the ACPGBI/BSG guidelines for the management of LNPCPs was used by a steering subcommittee to identify various parameters pertaining to the decision-making processes in the assessment and management of LNPCPs. A modified Delphi consensus process was then used for voting on proposed parameters over multiple voting rounds with at least 80% agreement defined as consensus. The minimum dataset was used in a pilot process to ensure rigidity and usability. RESULTS: A 23-parameter minimum dataset with parameters relating to patient and lesion factors, including six parameters relating to image retrieval, was formulated over four rounds of voting with two pilot processes to test rigidity and usability. CONCLUSION: This paper describes the development of the first reported evidence-based and expert consensus minimum dataset for the management of LNPCPs. It is anticipated that this dataset will allow comprehensive and standardized lesion assessment to improve decision-making in the assessment and management of LNPCPs.


Asunto(s)
Toma de Decisiones Clínicas/métodos , Pólipos del Colon , Cirugía Colorrectal/normas , Consenso , Gastroenterología/normas , Humanos , Irlanda , Sociedades Médicas , Reino Unido
2.
Gut ; 64(12)Dec. 2015.
Artículo en Inglés | BIGG - guías GRADE | ID: biblio-965097

RESUMEN

These guidelines provide an evidence-based framework for the management of patients with large non-pedunculated colorectal polyps (LNPCPs), in addition to identifying key performance indicators (KPIs) that permit the audit of quality outcomes. These are areas not previously covered by British Society of Gastroenterology (BSG) Guidelines.A National Institute of Health and Care Excellence (NICE) compliant BSG guideline development process was used throughout and the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool was used to structure the guideline development process. A systematic review of literature was conducted for English language articles up to May 2014 concerning the assessment and management of LNPCPs. Quality of evaluated studies was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) Methodology Checklist System. Proposed recommendation statements were evaluated by each member of the Guideline Development Group (GDG) on a scale from 1 (strongly agree) to 5 (strongly disagree) with >80% agreement required for consensus to be reached. Where consensus was not reached a modified Delphi process was used to re-evaluate and modify proposed statements until consensus was reached or the statement discarded. A round table meeting was subsequently held to finalise recommendations and to evaluate the strength of evidence discussed. The GRADE tool was used to assess the strength of evidence and strength of recommendation for finalised statements.KPIs, a training framework and potential research questions for the management of LNPCPs were also developed. It is hoped that these guidelines will improve the assessment and management of LNPCPs.


Asunto(s)
Humanos , Enfermedades del Recto/diagnóstico , Inhibidores de Agregación Plaquetaria , Pólipos del Colon/diagnóstico , Endoscopía Gastrointestinal , Indicadores de Calidad de la Atención de Salud , Anticoagulantes
4.
Proc Soc Exp Biol Med ; 148(4): 1173-6, 1975 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-1129331

RESUMEN

The effects of indomethacin on furosemide induced changes in renal blood flow were determined in dogs. Furosemide alone caused an increase in total renal blood flow while indomethacin alone decreased renal blood flow. When furosemide was administered to animals pretreated with indomethacin the increase in renal blood flow was blocked. Changes in intrarenal blood flow distribution were also measured using radioactive microspheres. The pattern of blood flow distribution after furosemide was modified in some of the animals pretreated with indomethacin. Stimulation of renin secretion occurred after furosemide in indomethacin-treated animals. The data suggest that the changes in renal blood flow produced by furosemide may be modulated by the prostaglandin system.


Asunto(s)
Furosemida/farmacología , Indometacina/farmacología , Riñón/irrigación sanguínea , Animales , Depresión Química , Perros , Furosemida/antagonistas & inhibidores , Riñón/efectos de los fármacos , Masculino , Microesferas , Flujo Sanguíneo Regional/efectos de los fármacos , Renina/metabolismo , Estimulación Química
5.
Am J Physiol ; 228(3): 850-3, 1975 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-163595

RESUMEN

Experiments were performed in dogs to determine the effects of the intravenous administration of the dipeptide hydrolase inhibitor SQ 20,881 on renal hemodynamics, intrarenal blood flow distribution, and renal function. Dipeptide hydrolase converts angiotensin I to angiotensin II and inactivates bradykinin. SQ 20,881 causes an inhibition of the vasoconstrictor response after angiotensin I and potentiation of the vasodilatory activity of bradykinin. Total renal blood flow, cortical distribution of blood flow, and glomerular filtration rate were determined. In seven animals administration of SQ 20,881 (1 mg/kg) resulted in a decrease in mean systemic blood pressure of 11 mmHg, an increase in total renal blood flow of 0.71 ml/min per g, and a significant fall in glomerular filtration rate. Fractional blood flow to the superficial cortex decreased and to the juxtamedullary cortex increased. Absolute flow was unchanged in the superficial cortex and increased significantly in the deep cortex. The findings are compatible with reported effects of bradykinin on intrarenal blood flow distribution, although the experiments do not distinguish between potentiation of bradykinin or inhibition of angiotensin I conversion.


Asunto(s)
Dipeptidasas/antagonistas & inhibidores , Riñón/irrigación sanguínea , Oligopéptidos/farmacología , Angiotensina II/metabolismo , Angiotensina II/farmacología , Inhibidores de la Enzima Convertidora de Angiotensina , Animales , Presión Sanguínea/efectos de los fármacos , Bradiquinina/farmacología , Perros , Tasa de Filtración Glomerular/efectos de los fármacos , Inulina/orina , Corteza Renal/irrigación sanguínea , Masculino , Natriuresis/efectos de los fármacos , Fosfatos/orina , Flujo Sanguíneo Regional/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...